Table 2.
Number of patients (%) with serious adverse events listed by preferred term and dose of paclitaxel micellar
| Preferred term | Dose of paclitaxel micellar | All patients (N = 34) | ||||
|---|---|---|---|---|---|---|
| 175 mg/m2 (N = 5)a | 200 mg/m2 (N = 3) | 225 mg/m2 (N = 6) | 250 mg/m2 (N = 14) | 275 mg/m2 (N = 6) | ||
| Ileus | 1 (20%) | 1 (33%) | 2 (6%) | |||
| Subileus | 1 (20%) | 1 (3%) | ||||
| Stomatitis | 1 (7%) | 1 (3%) | ||||
| Small intestinal obstruction | 1 (17%) | 1 (3%) | ||||
| Pyrexia | 1 (20%) | 1 (17%) | 1 (17%) | 3 (9%) | ||
| Abdominal infection | 1 (20%) | 1 (3%) | ||||
| Sepsis | 1 (7%) | 1 (3%) | ||||
| Haemoglobin decreased | 1 (7%) | 1 (17%) | 2 (6%) | |||
| Arthralgia | 1 (7%) | 1 (3%) | ||||
| Myalgia | 1 (7%) | 1 (3%) | ||||
| Syncope | 1 (7%) | 1 (3%) | ||||
| Urinary retention | 1 (7%) | 1 (3%) | ||||
| Dyspnoea | 1 (7%) | 1 (3%) | ||||
| Thrombosis | 1 (17%) | 1 (3%) | ||||
aData from the 2 patients receiving dose escalations are included at dose level 175 mg/m2